ClinicalTrials.gg
CompletedNCT00500903Updated Mar 14, 2019Results posted

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Alisertib in Advanced Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
87
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of MLN8237 when given by mouth (PO) for a minimum of 7 and a maximum of 21 consecutive days, followed by a 14-day recovery period.

Read the detailed description

The drug tested in this study is called alisertib. Alisertib is being tested to treat people who have advanced malignancies. This study determined the dose-limiting toxicity, maximum tolerated dose, safety and pharmacokinetics (how the drug moves through the body) for alisertib when given once or twice a day for 7 to 21 days. This open label study enrolled 87 participants. Participants were enrolled in one of 3 treatment groups:

  • Powder-in-Capsule (PIC) Dose Escalation (alisertib 5, 10, 20, 40, 80, 110 or 150 mg PIC , once daily (QD) for 7 days (D),or alisertib 25 mg, PIC, orally, QD 14D, or alisertib 25, 50 or 70 mg, PIC, orally, QD 21D, or alisertib 50 or 60 mg, PIC, orally, twice daily (BID) 7D, alisertib 40 mg, PIC, orally, BID 14D
  • ECT Dose Escalation (alisertib 10 or 20 mg, Enteric-coated Tablets (ECT), orally, QD for 7 to 21 days
  • Relative Bioavailability (alisertib 40 mg ECT or PIC, orally, BID 7D in cycle 1, followed by alisertib 40 mg in the opposite formulation (PIC or ECT) orally, BID 7D in cycle 2, followed by alisertib 50 mg PIC orally, BID 7D in each additional All participants received treatment until their disease progressed or they experienced unacceptable alisertib-related toxicity. This multi-center trial was conducted in the United States. The overall time to participate in this study was 1011 days. Participants made multiple visits to the clinic, including a final visit 30 days after receiving their last dose of alisertib for a follow-up assessment.
02

Conditions studied

  • Advanced Malignancies

Keywords

  • Drug therapy
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted before Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed and/or advanced solid tumors (including lymphomas) for which no effective standard treatment is available
  • Aged 18 years or more
  • (ECOG) performance status 0 or 1
  • Expected survival longer than 3 months from enrollment in the study
  • Radiographically or clinically evaluable tumor; however, as defined by () criteria is not required for participation in this study
  • Suitable venous access for the conduct of blood sampling for MLN8237 PK
  • Recovered from the reversible effects of prior antineoplastic therapy (with the exception of alopecia and grade 1 neuropathy) with at least 4 weeks elapsed since the last exposure to cytotoxic chemotherapy or to radiotherapy and at least 6 weeks elapsed since exposure to nitrosoureas or mitomycin C. Participants treated with fully human monoclonal antibodies must not have received treatment with such antibodies for at least 6 weeks, and those treated with chimeric monoclonal antibodies must not have received treatment with such antibodies for at least 4 weeks. Participants treated with noncytotoxic small molecule drugs (eg, tyrosine kinase inhibitors, such as Tarceva®, and hormonal agents, such as Femara®) must not have received treatment with these drugs for at least 2 weeks before the first dose of MLN8237 is given.
  • Male participants must use an appropriate method of barrier (eg, condoms) and inform any sexual partners that they must also use a reliable method of contraception (eg, birth control pills) from the time of until 3 months after the last dose of study treatment.
  • Female participants must be , surgically sterilized, or willing to use reliable methods of birth control (eg, a hormonal contraceptive, an intrauterine device, diaphragm with spermicide, or abstinence) and inform male sexual partners that they must also use a reliable method of contraception (eg, condoms) from the time of informed consent until 3 months after the last dose of study treatment.
  • Willing and able to give written informed consent before the conduct of any study related procedure that is not part of normal medical care, and willing to comply with the protocol

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating
  • Major surgery or serious infection within the 28 days preceding the first dose of study treatment
  • Life-threatening illness or uncontrolled medical illness unrelated to cancer
  • Ongoing nausea or vomiting of any severity
  • > Grade 1 diarrhea
  • Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN8237. Examples include but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease.
  • History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe .
  • Difficulty swallowing capsules
  • Inability to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose of MLN8237
  • Received more than 4 previous cytotoxic chemotherapeutic regimens including regimens used as or neo-adjuvant therapies. There is no limit on the number of noncytotoxic therapies (eg, hormonal and immunologic) that participants may have received. Tyrosine kinase inhibitors (eg, Tarceva and Iressa®) are considered noncytotoxic compounds.
  • Prior treatment with high-dose chemotherapy, defined as chemotherapy requiring the use of peripheral blood or bone marrow stem cell support for hematopoietic reconstitution
  • Prior treatment with radiation therapy involving ≥25% of the hematopoietically active bone marrow
  • Clinical and/or radiographic evidence of cerebral . However, participants who have a history of central nervous system (CNS) metastasis but who have no radiographic or clinical evidence of residual tumor (eg, following complete surgical resection or stereotactic radiosurgery) are not excluded from participation in this study
  • \<1500/mm\^3; count \<100,000/mm\^3
  • Serum creatinine >1.6 mg/dl or a measured or estimated \<40 mL/minute
  • >1.5 times the (ULN); (AST)/alanine aminotransferase (ALT) >2.5 times the ULN, and alkaline phosphatase (ALP) >2.5 times the ULN. Both the AST and ALP may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of metastatic disease to liver and/or to bone; however, the ALT must in all circumstances be \<2.5 times the ULN
  • Abnormalities on 12-lead (ECG) considered by the investigator to be or baseline prolongation of the rate- interval (eg, repeated demonstration of QTc interval > 450 milliseconds)
  • (LVEF) \< 50%
  • Known or suspected (HIV) positive or surface antigen-positive status, or known or suspected active infection. Testing for these agents is not required in the absence of clinical findings or suspicion.
  • Less than 4 weeks between the last dose of an agent and the first dose of MLN8237
  • Admission or evidence of benzodiazepine dependence or abuse and/or alcohol abuse or an inability to restrict consumption of alcohol to no more than 1 standard unit of alcohol per day during the study and for 30 days from the last dose of study treatment. A standard unit of alcohol is defined as one 12-oz (150mL) beer, 1.5 oz (45mL) of 80-proof alcohol, or one 6-oz (175mL) glass of wine.
  • Lactose intolerant, for the food effect cohort only.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    PIC Dose Escalation

    Alisertib 5, 10, 20, 40, 80, 110 or 150 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 7 to 21 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 51 cycles).

    Drug: Alisertib

  • Experimental
    ECT Dose Escalation

    Alisertib 10 or 20 mg, Enteric-coated Tablet (ECT) formulation, orally, once daily (QD) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 2 cycles).

    Drug: Alisertib

  • Experimental
    Relative Bioavailability

    Alisertib 40 mg ECT or PIC formulation, orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 1, followed by alisertib 40 mg in the opposite formulation (PIC or ECT) orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 2, followed by alisertib 50 mg PIC formulation orally, twice daily (BID) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 9 cycles).

    Drug: Alisertib

Interventions

  • Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicity (DLT)

    DLT was evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and was defined as any of the following events related to therapy with alisertib: 1. Grade 4 neutropenia lasting ≥7 consecutive days 2. Grade 4 neutropenia with fever and/or infection 3. Platelet count \<25,000/mm\^3 4. Grade 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis 5. Grade 3 or greater diarrhea despite maximal supportive therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\<1 week) Grade 3 fatigue 7. Treatment delay of \>1 week due to failure of adequate hematologic or nonhematologic recovery from previous cycle of treatment 8. Other alisertib-related nonhematologic toxicities ≥Grade 2 that, in the opinion of the investigator, required a dose reduction or discontinuation of therapy with alisertib.

    Time frame: Cycle 1 Day 1 up to Day 35 (alisertib daily for 7 to 21 days followed by a 14-day recovery period)

  2. Maximum Tolerated Dose (MTD) of Alisertib

    MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 patients.

    Time frame: From first dose of study drug to 30 days after the last dose (up to 1011 days)

  3. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: From first dose of study drug to 30 days after the last dose (up to 1011 days)

Secondary outcomes

  1. Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose

  2. Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose

  3. AUCt: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose

  4. Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing

    Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose

  5. Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing

    Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose

  6. Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing

    Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose

  7. CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing

    Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose

  8. Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose

  9. CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose

  10. Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose

  11. Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose

  12. AUCt: Area Under the Concentration--Time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose

  13. Terminal Half-Life for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing

    Time frame: Cycle 1 Day 14 predose and at multiple time-points (up to 10 hours) postdose

  14. Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing

    Time frame: Cycle 1 Days 7 and 14 predose and at multiple time-points (up to 10 hours) postdose

  15. Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing

    Time frame: Cycle 1 Days 7 and 14 predose and at multiple time-points (up to 10 hours) postdose

  16. CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing

    Time frame: Cycle 1 Days 7 and 14 predose and at multiple time-points (up to 10 hours) postdose

  17. Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose

  18. CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose

  19. Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints up to 24 hours postdose and Days 14 and 21 predose and at multiple time points (up to 10 hours) postdose

  20. Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints up to 24 hours postdose and Days 14 and 21 predose and at multiple time points (up to 10 hours) postdose

  21. AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple timepoints up to 24 hours postdose and Days 14 and 21 predose and at multiple time points (up to 10 hours) postdose

  22. Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing

    Time frame: Cycle 1 Day 21 predose and at multiple time points (up to 10 hours) postdose

  23. Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing

    Time frame: Cycle 1 Days 14 and 21 predose and at multiple timepoints (up to 10 hours) postdose

  24. Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing

    Time frame: Cycle 1 Days 14 and 21 predose and at multiple timepoints up to 10 hours postdose

  25. CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing

    Time frame: Cycle 1 Days 14 and 21 predose and at multiple timepoints up to 10 hours postdose

  26. Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time points (up to 24 hours) postdose

  27. CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time points (up to 24 hours) postdose

  28. Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose

  29. Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose

  30. AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose

  31. Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing

    Time frame: Cycle 1 Day 8

  32. Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing

    Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose

  33. Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing

    Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose

  34. CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing

    Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose

  35. Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose

  36. CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose

  37. Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing

    Time frame: Cycle 1 Days 1 and 7 predose and at multiple time-points (up to 10 hours) postdose

  38. Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing

    Time frame: Cycle 1 Days 1 and 7 predose and at multiple time-points (up to 10 hours) postdose

  39. AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing

    Time frame: Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose

  40. AUCt: Area Under the Concentration-time Curve From Time 0 to Time t as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7

    Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose

  41. Cmax: Maximum Observed Concentration as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7

    Time frame: Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose

  42. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 7 Days (QD7D) Dosing

    Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose

  43. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 7 Days (QD7D) Dosing

    Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose

  44. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 14 Days (QD14D) Dosing

    Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose

  45. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 14 Days (QD14D) Dosing

    Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose

  46. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 21 Days (QD21D) Dosing

    Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Days 7 and 21, 6 hours postdose

  47. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 21 Days (QD21D) Dosing

    Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Days 7 and 21, 6 hours postdose

  48. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 7 Days (BID7D) Dosing

    Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Day 7, 6 hours postdose

  49. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 7 Days (BID7D) Dosing

    Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Day 7, 6 hours postdose

  50. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing

    Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 7, 6 hours postdose

  51. Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing

    Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Cycle 1 Day 7, 6 hours postdose

  52. Number of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1

    One peripheral blood sample (approximately 4 mL) was to be obtained on Day 1 of Cycle 1 prior to the first dose of alisertib to genotype patients for polymorphisms in UGT1A1 because UGT1A1 is one of the enzymes responsible for glucuronidation of alisertib, which is expected to contribute to the clearance of alisertib. wt=wild type \*28=polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression.

    Time frame: Cycle 1 Day 1 predose

  53. Best Overall Response Based on Investigator Assessment

    Best overall response is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. According to RECIST: CR is defined as disappearance of all target and nontarget lesions and normalization of tumor marker level (if applicable); PR is defined as ≥30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, persistence of 1 or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

    Time frame: Beginning at the end of Cycle 2, every 2 cycles until progressive disease (PD); Participants who discontinue study drug before PD: Follow-Up (FU) every 8-12 weeks until PD or as per institutional practice (Up to 33.2 months)

  54. Duration Of Response (DOR)

    DOR is defined as the time from the date of first documentation of a confirmed response to the date of first documented PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions.

    Time frame: Beginning at the end of Cycle 2, every 2 cycles until progressive disease (PD); Participants who discontinue study drug before PD: Follow-Up (FU) every 8-12 weeks until PD or as per institutional practice (Up to 33.2 months)

  55. Effect of Food on the Pharmacokinetics (PK) of Alisertib

    The effects of food on the PK of alisertib were to be evaluated using the preferred alisertib regimen (unit dose and formulation) based on the results from the relative bioavailability study.

    Time frame: Up to 6 months

07

Results

Posted Mar 14, 2019

Participant flow

Participants took part in the study at 3 investigative sites in the United States from 15 May 2007 to 23 February 2011.

Participant flow — Overall Study
MilestonePIC Dose EscalationECT Dose EscalationRelative Bioavailability
Started65220
Completed000
Not completed65220
Withdrew: Occurrence of adverse event(s)1000
Withdrew: Unsatisfactory therapeutic response200
Withdrew: Progressive disease41215
Withdrew: Patient declined further treatment003
Withdrew: Symptomatic deterioration200
Withdrew: Reason not specified1002

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicity (DLT)

DLT was evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and was defined as any of the following events related to therapy with alisertib: 1. Grade 4 neutropenia lasting ≥7 consecutive days 2. Grade 4 neutropenia with fever and/or infection 3. Platelet count \<25,000/mm\^3 4. Grade 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis 5. Grade 3 or greater diarrhea despite maximal supportive therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\<1 week) Grade 3 fatigue 7. Treatment delay of \>1 week due to failure of adequate hematologic or nonhematologic recovery from previous cycle of treatment 8. Other alisertib-related nonhematologic toxicities ≥Grade 2 that, in the opinion of the investigator, required a dose reduction or discontinuation of therapy with alisertib.

Time frame:
Cycle 1 Day 1 up to Day 35 (alisertib daily for 7 to 21 days followed by a 14-day recovery period)
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicity (DLT)
participantsAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7DAlisertib 25 mg PIC QD 14DAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21DAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7DAlisertib 40 mg PIC BID 14DAlisertib 10 mg ECT QD7Alisertib 20 mg ECT QD7
Number of Participants With Dose-Limiting Toxicity (DLT)0000013000122200
PrimaryMaximum Tolerated Dose (MTD) of Alisertib

MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 patients.

Time frame:
From first dose of study drug to 30 days after the last dose (up to 1011 days)
Reported as:
Number · mg BID for 7 Days
Maximum Tolerated Dose (MTD) of Alisertib
mg BID for 7 DaysAlisertib
Maximum Tolerated Dose (MTD) of Alisertib50
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
From first dose of study drug to 30 days after the last dose (up to 1011 days)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPIC Dose EscalationECT Dose EscalationRelative Bioavailability
AEs65220
SAEs2601
SecondaryCmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
nMAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
Day 1208.4 ± 27.96279.1 ± 46.20759.3 ± 11.821245.4 ± 20.601661.3 ± 45.202717.8 ± 44.624260.3 ± 42.62
Day 7285.7 ± 32.74931.5 ± 81.681114.1 ± 36.961681.6 ± 64.622376.3 ± 51.063586.4 ± 48.284467.8 ± 24.58
SecondaryTmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Median · hours (h)
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
hours (h)Alisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
Day 12.000 (1.50 to 3.00)2.000 (1.50 to 3.00)1.500 (1.50 to 1.50)2.000 (1.50 to 6.00)2.000 (1.50 to 3.00)2.000 (1.48 to 5.57)2.000 (1.45 to 3.00)
Day 71.500 (1.00 to 1.50)3.750 (1.50 to 6.00)1.500 (1.50 to 2.00)2.000 (1.97 to 6.00)2.000 (1.98 to 3.05)3.710 (1.42 to 6.02)2.000 (1.48 to 3.93)
SecondaryAUCt: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Geometric mean · nM*h
AUCt: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
nM*hAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
Day 11682.4 ± 31.062525.8 ± 21.875772.1 ± 10.6812045.4 ± 57.0120958.1 ± 38.9229460.7 ± 39.4338582.1 ± 45.95
Day 72919.5 ± 32.3110602.9 ± 107.8710927.5 ± 45.2721976.0 ± 96.6427825.5 ± 53.5946271.1 ± 33.3853031.9 ± 26.22
SecondaryTerminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame:
Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · h
Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
hAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing24.950 ± 20.435435.150 ± 23.405226.400 ± 19.768418.155 ± 12.508739.333 ± 18.800613.427 ± 4.346516.766 ± 9.7804
SecondaryAccumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame:
Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
ratioAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing1.753 ± 0.27546.350 ± 7.24082.037 ± 0.97081.997 ± 0.93931.535 ± 0.33231.677 ± 0.67881.588 ± 0.4129
SecondaryPeak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame:
Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · ratio
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
ratioAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing4.107 ± 0.84605.195 ± 3.95275.430 ± 2.48563.907 ± 2.39443.850 ± 2.06124.922 ± 2.58904.610 ± 0.5314
SecondaryCLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame:
Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Geometric mean · liters (L)/h
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
liters (L)/hAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing3.302 ± 35.89151.817 ± 107.83473.525 ± 49.12673.511 ± 72.13465.545 ± 41.02584.348 ± 61.52665.450 ± 37.3021
SecondaryAe: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Reported as:
Mean · ng
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
ngAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing0.0 ± 0.000.0 ± 0.000.0 ± 0.004806.7 ± 8325.3918815.0 ± 1675.8413813.3 ± 16387.2214473.3 ± 15603.71
SecondaryCLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Reported as:
Mean · L/h
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing
L/hAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 7 Days (QD7D) Dosing0.0012630 ± NA0.0013860 ± NA0.0009414 ± 0.000639560.0006710 ± 0.00060091
SecondaryCmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
nMAlisertib 25 mg PIC QD 14D
Day 1778.7 ± 24.28
Day 7995.5 ± 43.21
Day 14808.9 ± 37.96
SecondaryTmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
hAlisertib 25 mg PIC QD 14D
Day 14.000 (2.00 to 8.88)
Day 72.000 (2.00 to 2.00)
Day 142.000 (1.098 to 2.00)
SecondaryAUCt: Area Under the Concentration--Time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Geometric mean · nM*h
AUCt: Area Under the Concentration--Time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
nM*hAlisertib 25 mg PIC QD 14D
Day 18061.6 ± 17.30
Day 78634.0 ± 42.70
Day 148978.0 ± 20.15
SecondaryTerminal Half-Life for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame:
Cycle 1 Day 14 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · h
Terminal Half-Life for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
hAlisertib 25 mg PIC QD 14D
Terminal Half-Life for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing65.67 ± 43.859
SecondaryAccumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame:
Cycle 1 Days 7 and 14 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
ratioAlisertib 25 mg PIC QD 14D
Day 71.203 ± 0.6964
Day 141.133 ± 0.2303
SecondaryPeak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame:
Cycle 1 Days 7 and 14 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · ratio
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
ratioAlisertib 25 mg PIC QD 14D
Day 76.877 ± 1.1151
Day 145.073 ± 2.2113
SecondaryCLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame:
Cycle 1 Days 7 and 14 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · L/h
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
L/hAlisertib 25 mg PIC QD 14D
Day 76.030 ± 2.9963
Day 145.433 ± 0.9808
SecondaryAe: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Reported as:
Mean · ng
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
ngAlisertib 25 mg PIC QD 14D
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing800.0 ± 1385.64
SecondaryCLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Reported as:
Mean · L/h
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing
L/hAlisertib 25 mg PIC QD 14D
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing0.0004930 ± NA
SecondaryCmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints up to 24 hours postdose and Days 14 and 21 predose and at multiple time points (up to 10 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
nMAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Day 1898.2 ± 86.351725.9 ± 54.702237.0 ± 54.18
Day 141343.3 ± 60.321722.0 ± 38.822598.3 ± 12.49
Day 211104.7 ± 45.151564.2 ± 38.801974.5 ± 59.49
SecondaryTmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints up to 24 hours postdose and Days 14 and 21 predose and at multiple time points (up to 10 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
hAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Day 12.020 (2.00 to 4.00)2.285 (2.00 to 4.00)2.000 (2.00 to 2.02)
Day 142.000 (2.00 to 2.18)2.000 (1.98 to 2.03)2.000 (2.00 to 2.05)
Day 212.000 (1.00 to 2.02)2.000 (1.93 to 9.92)2.000 (1.00 to 6.00)
SecondaryAUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple timepoints up to 24 hours postdose and Days 14 and 21 predose and at multiple time points (up to 10 hours) postdose
Reported as:
Geometric mean · nM*h
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
nM*hAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Day 110058.0 ± 66.8514686.6 ± 44.0422114.8 ± 68.66
Day 1415131.7 ± 49.8917168.2 ± 32.0923197.2 ± 17.75
Day 2113199.3 ± 70.0519336.3 ± 26.8523499.8 ± 65.64
SecondaryTerminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame:
Cycle 1 Day 21 predose and at multiple time points (up to 10 hours) postdose
Reported as:
Mean · h
Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
hAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing31.667 ± 6.712223.650 ± 16.948722.378 ± 19.8802
SecondaryAccumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame:
Cycle 1 Days 14 and 21 predose and at multiple timepoints (up to 10 hours) postdose
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
ratioAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Day 141.560 ± 0.55431.230 ± 0.41931.440 ± 0.1493
Day 211.560 ± 1.05161.373 ± 0.44741.335 ± 0.4749
SecondaryPeak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame:
Cycle 1 Days 14 and 21 predose and at multiple timepoints up to 10 hours postdose
Reported as:
Mean · ratio
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
ratioAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Day 144.773 ± 0.90017.543 ± 5.49826.392 ± 2.0824
Day 213.637 ± 1.86754.157 ± 2.10515.570 ± 2.5772
SecondaryCLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame:
Cycle 1 Days 14 and 21 predose and at multiple timepoints up to 10 hours postdose
Reported as:
Geometric mean · L/h
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
L/hAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Day 143.181 ± 42.57065.612 ± 28.68815.825 ± 17.7291
Day 213.656 ± 89.57504.984 ± 25.69455.745 ± 42.3818
SecondaryAe: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time points (up to 24 hours) postdose
Reported as:
Mean · ng
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
ngAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing3047.7 ± 5278.715766.7 ± 7971.959391.4 ± 11410.18
SecondaryCLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time points (up to 24 hours) postdose
Reported as:
Mean · L/h
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing
L/hAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing0.0008640 ± NA0.0012323 ± 0.001118400.0007865 ± 0.00042447
SecondaryCmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
nMAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
Day 11581.1 ± 37.341867.1 ± 29.03
Day 73376.4 ± 41.743080.8 ± 38.79
SecondaryTmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
hAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
Day 12.000 (1.98 to 8.00)2.000 (1.60 to 4.00)
Day 72.015 (0.98 to 6.05)2.000 (1.98 to 6.03)
SecondaryAUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose and Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Geometric mean · nM*h
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
nM*hAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
Day 111166.3 ± 37.4513200.4 ± 26.70
Day 732291.5 ± 40.8227386.1 ± 37.43
SecondaryTerminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame:
Cycle 1 Day 8
Reported as:
Mean · h
Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
hAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
Terminal Half-Life (t1/2) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing20.215 ± 15.508318.200 ± 3.2212
SecondaryAccumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame:
Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · ratio
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
ratioAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
Accumulation Ratio (Rac) for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing2.474 ± 1.04672.543 ± 0.1950
SecondaryPeak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame:
Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · ratio
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
ratioAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
Peak/Trough Ratio for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing2.193 ± 1.13461.890 ± 0.2012
SecondaryCLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame:
Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Geometric mean · L/h
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
L/hAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing2.984 ± 43.87194.220 ± 47.9681
SecondaryAe: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Reported as:
Mean · ng
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
ngAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
Ae: Amount of Alisertib Excreted in Urine Over the Collection Period for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing13775.0 ± 7937.148498.3 ± 6866.09
SecondaryCLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Reported as:
Mean · ng
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing
ngAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
CLr: Renal Clearance of Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 7 Days (BID7D) Dosing0.001 ± 0.00110.001 ± 0.0004
SecondaryCmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing
Time frame:
Cycle 1 Days 1 and 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Geometric mean · nM
Cmax: Maximum Observed Concentration for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing
nMAlisertib 40 mg PIC BID 14D
Day 11236.6 ± 37.29
Day 72060.0 ± NA
SecondaryTmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing
Time frame:
Cycle 1 Days 1 and 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Median · h
Tmax: Time of First Occurrence of Cmax for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing
hAlisertib 40 mg PIC BID 14D
Day 13.00 (2.0 to 4.0)
Day 71.70 (1.7 to 1.7)
SecondaryAUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing
Time frame:
Cycle 1 Day 1 predose and at multiple time-points (up to 24 hours) postdose
Reported as:
Geometric mean · nM*h
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing
nM*hAlisertib 40 mg PIC BID 14D
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Alisertib as Powder-in-Capsule (PIC) With Twice Daily for 14 Days (BID14D) Dosing9684.8 ± 71.50
SecondaryAUCt: Area Under the Concentration-time Curve From Time 0 to Time t as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7
Time frame:
Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · nM*h
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7
nM*hAlisertib 40 mg ECT BID 7DAlisertib 40 mg PIC BID 7D
AUCt: Area Under the Concentration-time Curve From Time 0 to Time t as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 712700.0 ± 6557.5814190.7 ± 7097.72
SecondaryCmax: Maximum Observed Concentration as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7
Time frame:
Cycle 1 Day 7 predose and at multiple time-points (up to 10 hours) postdose
Reported as:
Mean · nM
Cmax: Maximum Observed Concentration as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 7
nMAlisertib 40 mg ECT BID 7DAlisertib 40 mg PIC BID 7D
Cmax: Maximum Observed Concentration as Assessment of Relative Bioavailability for Alisertib as Enteric-coated Tablet (ECT) Versus PIC at Day 71666.1 ± 765.282027.9 ± 928.96
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 7 Days (QD7D) Dosing

Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose
Reported as:
Mean · mitotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 7 Days (QD7D) Dosing
mitotic cells/millimeter of BELAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
Day 1, Hour 60.405 ± 0.27010.614 ± 0.54370.263 ± 0.14610.168 ± 0.51460.488 ± 1.02150.261 ± 0.45970.865 ± 0.9420
Day 1, Hour 240.019 ± 0.1914-0.103 ± 0.01860.005 ± 0.07090.141 ± 0.38520.108 ± 0.40811.764 ± 2.63800.239 ± 0.6992
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 7 Days (QD7D) Dosing

Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose
Reported as:
Mean · apoptotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 7 Days (QD7D) Dosing
apoptotic cells/millimeter of BELAlisertib 5 mg PIC QD 7DAlisertib 10 mg PIC QD 7DAlisertib 20 mg PIC QD 7DAlisertib 40 mg PIC QD 7DAlisertib 80 mg PIC QD 7DAlisertib 110 mg PIC QD 7DAlisertib 150 mg PIC QD 7D
Day 1, Hour 60.010 ± 0.1175-0.090 ± 0.12780.042 ± 0.07310.040 ± 0.07010.121 ± 0.13170.036 ± 0.0530-0.042 ± 0.1262
Day 1, Hour 240.009 ± 0.11640.065 ± 0.14040.000 ± 0.00000.037 ± 0.06340.074 ± 0.12860.151 ± 0.17210.139 ± 0.2069
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 14 Days (QD14D) Dosing

Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose
Reported as:
Mean · mitotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 14 Days (QD14D) Dosing
mitotic cells/millimeter of BELAlisertib 25 mg PIC QD 14D
Day 1, Hour 60.134 ± 0.1723
Day 1, Hour 240.047 ± 0.0589
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 14 Days (QD14D) Dosing

Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose
Reported as:
Mean · apoptotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 14 Days (QD14D) Dosing
apoptotic cells/millimeter of BELAlisertib 25 mg PIC QD 14D
Day 1, Hour 60.000 ± 0.0000
Day 1, Hour 240.000 ± 0.0000
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 21 Days (QD21D) Dosing

Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Days 7 and 21, 6 hours postdose
Reported as:
Mean · mitotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Once Daily for 21 Days (QD21D) Dosing
mitotic cells/millimeter of BELAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Day 1, Hour 60.380 ± 0.41650.405 ± 0.46900.510 ± NA
Day 1, Hour 240.021 ± 0.10810.082 ± 0.17960.289 ± 0.5746
Day 7, Hour 6——0.479 ± 0.3040
Day 21, Hour 6—0.045 ± NA0.742 ± 0.5782
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 21 Days (QD21D) Dosing

Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Days 7 and 21, 6 hours postdose
Reported as:
Mean · apoptotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Once Daily for 21 Days (QD21D) Dosing
apoptotic cells/millimeter of BELAlisertib 25 mg PIC QD 21DAlisertib 50 mg PIC QD 21DAlisertib 70 mg PIC QD 21D
Day 1, Hour 60.122 ± 0.21170.000 ± 0.00000.000 ± NA
Day 1, Hour 240.042 ± 0.07220.042 ± 0.07190.000 ± 0.0000
Day 7, Hour 6——0.000 ± 0.0000
Day 21, Hour 6—0.099 ± NA0.032 ± 0.0552
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 7 Days (BID7D) Dosing

Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Day 7, 6 hours postdose
Reported as:
Mean · mitotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 7 Days (BID7D) Dosing
mitotic cells/millimeter of BELAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
Day 1, Hour 60.054 ± 0.30220.364 ± 0.2574
Day 1, Hour 242.578 ± 2.28751.435 ± 0.8329
Day 7, Hour 65.486 ± 5.8688—
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 7 Days (BID7D) Dosing

Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 1, 6 hours and 24 hours postdose and Day 7, 6 hours postdose
Reported as:
Mean · apoptotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 7 Days (BID7D) Dosing
apoptotic cells/millimeter of BELAlisertib 50 mg PIC BID 7DAlisertib 60 mg PIC BID 7D
Day 1, Hour 6-0.016 ± 0.04940.020 ± 0.0491
Day 1, Hour 240.055 ± 0.16910.080 ± 0.1958
Day 7, Hour 62.142 ± 3.2510—
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing

Mitotic index was defined as the mean number of mitotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Mitotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with fluorescent-tagged antibodies specific to 2 mitotic markers-serine 10 phosphohistone H3 (pHistH3) and MPM2. Deoxyribonucleic acid (DNA) was stained with a fluorescent marker as well. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 7, 6 hours postdose
Reported as:
Mean · mitotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing
mitotic cells/millimeter of BELAlisertib 40 mg PIC BID 14D
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Mitotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing1.507 ± NA
SecondaryChange From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing

Apoptotic index was defined as the mean number of apoptotic cells per millimeter (mm) length of the basoepithelial layer (BEL). Apoptotic cells were counted manually within the BEL of 4, 5 µM skin sections by staining with hematoxylin-eosin. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Cycle 1 Day 7, 6 hours postdose
Reported as:
Mean · apoptotic cells/millimeter of BEL
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing
apoptotic cells/millimeter of BELAlisertib 40 mg PIC BID 14D
Change From Baseline in Alisertib Skin Punch Biopsy as Measured by Apoptotic Index With PIC Twice Daily for 14 Days (BID14D) Dosing2.837 ± NA
SecondaryNumber of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1

One peripheral blood sample (approximately 4 mL) was to be obtained on Day 1 of Cycle 1 prior to the first dose of alisertib to genotype patients for polymorphisms in UGT1A1 because UGT1A1 is one of the enzymes responsible for glucuronidation of alisertib, which is expected to contribute to the clearance of alisertib. wt=wild type \*28=polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression.

Time frame:
Cycle 1 Day 1 predose
Reported as:
Number · participants
Number of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1
participantsAlisertib
wt/wt38
wt/*2830
*28/*289
*28/other4
other/other2
Not Determined1
Missing3
SecondaryBest Overall Response Based on Investigator Assessment

Best overall response is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. According to RECIST: CR is defined as disappearance of all target and nontarget lesions and normalization of tumor marker level (if applicable); PR is defined as ≥30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, persistence of 1 or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

Time frame:
Beginning at the end of Cycle 2, every 2 cycles until progressive disease (PD); Participants who discontinue study drug before PD: Follow-Up (FU) every 8-12 weeks until PD or as per institutional practice (Up to 33.2 months)
Reported as:
Number · percentage of participants
Best Overall Response Based on Investigator Assessment
percentage of participantsAlisertib
Best Overall Response Based on Investigator Assessment1
SecondaryDuration Of Response (DOR)

DOR is defined as the time from the date of first documentation of a confirmed response to the date of first documented PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions.

Time frame:
Beginning at the end of Cycle 2, every 2 cycles until progressive disease (PD); Participants who discontinue study drug before PD: Follow-Up (FU) every 8-12 weeks until PD or as per institutional practice (Up to 33.2 months)
Reported as:
Number · days
Duration Of Response (DOR)
daysAlisertib
Duration Of Response (DOR)470
SecondaryEffect of Food on the Pharmacokinetics (PK) of Alisertib

The effects of food on the PK of alisertib were to be evaluated using the preferred alisertib regimen (unit dose and formulation) based on the results from the relative bioavailability study.

Time frame:
Up to 6 months

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study drug to 30 days after the last dose (up to 1011 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PIC Dose Escalation—26/65 (40%)65/65 (100%)
ECT Dose Escalation—0/2 (0%)2/2 (100%)
Relative Bioavailability—1/20 (5%)20/20 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventPIC Dose EscalationECT Dose EscalationRelative Bioavailability
Febrile neutropeniaBlood and lymphatic system disorders5/650/21/20
AnaemiaBlood and lymphatic system disorders4/650/20/20
ThrombocytopeniaBlood and lymphatic system disorders4/650/20/20
Klebsiella bacteraemiaInfections and infestations1/650/21/20
Enterococcal bacteraemiaInfections and infestations0/650/21/20
Bile duct obstructionHepatobiliary disorders0/650/21/20
Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/650/21/20
Back painMusculoskeletal and connective tissue disorders0/650/21/20
Neck painMusculoskeletal and connective tissue disorders0/650/21/20
Deep vein thrombosisVascular disorders0/650/21/20
Most frequent other events
Showing 10 of 104
Most frequent other events
EventPIC Dose EscalationECT Dose EscalationRelative Bioavailability
FatigueGeneral disorders32/652/212/20
AnaemiaBlood and lymphatic system disorders24/652/26/20
NauseaGastrointestinal disorders39/651/26/20
DiarrhoeaGastrointestinal disorders34/651/26/20
VomitingGastrointestinal disorders24/651/22/20
StomatitisGastrointestinal disorders15/651/25/20
Oral painGastrointestinal disorders3/651/20/20
AstheniaGeneral disorders11/651/21/20
PainGeneral disorders1/651/21/20
AnorexiaMetabolism and nutrition disorders30/651/23/20

Baseline characteristics

The Safety Population included all participants who received any amount of study drug.

Age, Continuous
Age, Continuous(years)PIC Dose EscalationECT Dose EscalationRelative BioavailabilityTotal
Mean61.6 ± 10.4457.0 ± 15.5656.9 ± 11.7160.4 ± 10.88
Sex: Female, Male
Sex: Female, Male(Participants)PIC Dose EscalationECT Dose EscalationRelative BioavailabilityTotal
Female331943
Male3211144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PIC Dose EscalationECT Dose EscalationRelative BioavailabilityTotal
Not Hispanic or Latino5622078
Not Reported7007
Hispanic or Latino2002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PIC Dose EscalationECT Dose EscalationRelative BioavailabilityTotal
White5521875
Black or African American90211
Other1001
Region of Enrollment
Region of Enrollment(participants)PIC Dose EscalationECT Dose EscalationRelative BioavailabilityTotal
United States6522087
Height
Height(cm)PIC Dose EscalationECT Dose EscalationRelative BioavailabilityTotal
Mean169.3 ± 10.06165.1 ± 0.00171.5 ± 12.51169.7 ± 10.55
Weight
Weight(kg)PIC Dose EscalationECT Dose EscalationRelative BioavailabilityTotal
Mean78.24 ± 18.13067.36 ± 11.22683.97 ± 21.70679.33 ± 18.976
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)PIC Dose EscalationECT Dose EscalationRelative BioavailabilityTotal
Mean1.91 ± 0.2631.75 ± 0.1471.99 ± 0.2941.92 ± 0.270
08

Study locations

1 site
  • Sarah Cannon Research Institute (SCRI)
    Nashville, Tennessee 37203, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2007 to primary completion in Aug 2010, 38 months.

Results were first posted in Mar 2019, 8 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2007
First posted
Jul 13, 2007
StartActual
May 15, 2007
Primary completionActual
Aug 1, 2010
CompletionActual
Feb 23, 2011
Results first posted
Mar 14, 2019
Last update
Mar 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00500903
Responsible party
Sponsor
First posted
Jul 13, 2007
Start date
May 15, 2007
Primary completion
Aug 1, 2010
Completion
Feb 23, 2011
Results posted
Mar 14, 2019
Last update
Mar 14, 2019

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion